0.95
Immunic Inc stock is traded at $0.95, with a volume of 1.07M.
It is up +0.54% in the last 24 hours and up +1.48% over the past month.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
See More
Previous Close:
$0.9449
Open:
$0.95
24h Volume:
1.07M
Relative Volume:
0.66
Market Cap:
$93.72M
Revenue:
-
Net Income/Loss:
$-93.61M
P/E Ratio:
-0.4502
EPS:
-2.11
Net Cash Flow:
$-71.16M
1W Performance:
+5.39%
1M Performance:
+1.48%
6M Performance:
-25.20%
1Y Performance:
-37.50%
Immunic Inc Stock (IMUX) Company Profile
Name
Immunic Inc
Sector
Industry
Phone
(332) 255-9818
Address
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
IMUX
Immunic Inc
|
0.95 | 96.53M | 0 | -93.61M | -71.16M | -2.11 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-25-25 | Initiated | William Blair | Outperform |
Nov-25-24 | Initiated | H.C. Wainwright | Buy |
Sep-09-24 | Resumed | Leerink Partners | Outperform |
Aug-27-24 | Initiated | B. Riley Securities | Buy |
Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Sep-19-22 | Resumed | H.C. Wainwright | Buy |
Apr-15-21 | Initiated | Aegis Capital | Buy |
Mar-24-21 | Initiated | JMP Securities | Mkt Outperform |
Oct-02-20 | Initiated | SVB Leerink | Outperform |
Aug-26-20 | Initiated | Piper Sandler | Overweight |
Aug-07-20 | Resumed | ROTH Capital | Buy |
Jul-20-20 | Initiated | BMO Capital Markets | Outperform |
Jun-05-20 | Initiated | Wedbush | Outperform |
May-11-20 | Initiated | H.C. Wainwright | Buy |
Mar-25-20 | Initiated | ROTH Capital | Buy |
Jul-11-19 | Initiated | Chardan Capital Markets | Buy |
View All
Immunic Inc Stock (IMUX) Latest News
Immunic to Participate in Investor, Scientific and Industry Conferences in June - MSN
Will Immunic Inc. benefit from geopolitical trendsInflation Watch & Consistent Profit Trade Alerts - thegnnews.com
Bollinger Bands Show Potential Breakout in Immunic Inc.2025 Support & Resistance & AI Powered Market Entry Strategies - classian.co.kr
Immunic Inc.’s Beta Climbs After Market VolatilityWeekly Volume Report & Growth Focused Entry Point Reports - kangso.co.kr
What are the future prospects of Immunic Inc.July 2025 Intraday Action & Consistent Return Strategy Ideas - thegnnews.com
Immunic (IMUX) Q2 Loss Widens 25% - AOL.com
Momentum Screeners Rank Immunic Inc. in Top 5 TodayCapital Protection Trading Strategies Gain Interest - beatles.ru
H.C. Wainwright reiterates Buy rating on Immunic stock, citing positive MS data - Investing.com
H.C. Wainwright reiterates Buy rating on Immunic stock, citing positive MS data By Investing.com - Investing.com South Africa
Immunic, Inc. Advances Multiple Sclerosis Drug Trials - TipRanks
Immunic, Inc. shares rise 3.21% premarket after Novartis' positive Phase III trial results for ianalumab in Sjögren's disease. - AInvest
William Blair Maintains Immunic(IMUX.US) With Buy Rating - 富途牛牛
Is Immunic Inc. stock a value trapInvestment Timing Signals - mustnews.co.kr
Technical signs of recovery in Immunic Inc.Free Risk-Adjusted Picks With Exit Strategy - Newser
Will Immunic Inc. price bounce be sustainableFree Smart Trade Plans With Risk Protection - Newser
Intraday pattern recognizer results for Immunic Inc.Free Early Entry Tips With Low Risk Zone - Newser
Immunic reports promising Phase 2 data for lead drug candidate in progressive MSICYMI - Proactive financial news
Is a relief rally coming for Immunic Inc. holdersConservative Investment Setup and Risk Analysis - Newser
Immunic Advances Phase 3 Trials and Financial Health - The Globe and Mail
Immunic: Q2 Earnings Snapshot - Connecticut Post
Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update - The Malaysian Reserve
Immunic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Small cap wrap: Immunic, Nextech3D.ai, EDM Resources, Alvopetro… - Proactive Investors
Immunic Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Immunic CEO on strong Q2 progress with vidofludimus calcium trials for MS - Proactive financial news
Immunic CEO Discusses Strong Q2 Progress in Vidofludimus Calcium Trials for MS Treatment - AInvest
Immunic advances MS drug program with Phase 3 trials fully enrolled - Proactive financial news
Immunic Q2 net loss widens, flags potential cash raise - AInvest
Biotech Immunic Q2 net loss widens, flags need to raise cash - MarketScreener
Immunic, Inc.: A High-Potential Biotech Play in the MS and GI Therapeutics Space - AInvest
EQS-News: Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Ariva
Immunic (IMUX) to Release Quarterly Earnings on Thursday - Defense World
Immunic, Inc. shares fall 1.43% after-hours as ImmunoPrecise Antibodies Ltd. reports earnings miss and auditor raises 'going concern' doubt. - AInvest
Immunic Inc. May Stage Comeback if Support HoldsAnalysts Use RSI to Predict UPLD’s Next MoveSecure Return Focused Investment Plan Released - beatles.ru
Immunic, Inc. shares fall 2.36% premarket after Sonnet BioTherapeutics' clinical trial data shows potential for SON-1010 in ovarian cancer. - AInvest
Immunic Inc. Stock Analysis and ForecastBreakout profit opportunities - Jammu Links News
When is Immunic Inc. stock expected to show significant growthMarket-crushing stock picks - Jammu Links News
How does Immunic Inc. compare to its industry peersMaximize gains with proven stock analysis - Jammu Links News
What is the dividend policy of Immunic Inc. stockMaximize returns with strategic portfolio planning - Jammu Links News
Should I hold or sell Immunic Inc. stock in 2025Invest confidently with real-time data analysis - Jammu Links News
What is the risk reward ratio of investing in Immunic Inc. stockSuperior profit margins - Jammu Links News
What are analysts’ price targets for Immunic Inc. in the next 12 monthsTrack high-yield stocks before they peak - Jammu Links News
What institutional investors are buying Immunic Inc. stockUnstoppable investment returns - Jammu Links News
What drives Immunic Inc. stock priceGain access to exclusive stock analysis - Jammu Links News
Immunic Inc Stock (IMUX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunic Inc Stock (IMUX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Tardio Jason | President and COO |
Jun 05 '25 |
Buy |
0.79 |
12,512 |
9,884 |
12,512 |
Vitt Daniel | CEO and Director |
Jun 04 '25 |
Buy |
0.77 |
15,000 |
11,550 |
29,000 |
Neermann Joerg | Director |
Jun 04 '25 |
Buy |
0.77 |
70,000 |
53,900 |
170,000 |
Neermann Joerg | Director |
Jun 05 '25 |
Buy |
0.76 |
30,000 |
22,800 |
200,000 |
Whaley Glenn | Chief Financial Officer |
Jun 03 '25 |
Buy |
0.71 |
45,000 |
32,076 |
95,510 |
Rudick Richard Alan | Director |
Jun 03 '25 |
Buy |
0.70 |
143,075 |
100,024 |
230,375 |
Rudick Richard Alan | Director |
Nov 12 '24 |
Buy |
1.15 |
87,300 |
100,369 |
87,300 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):